Professor of Medicine
Duke University Medical Center
Disclosure(s): Affinergy, Janssen, Contrafect: Advisor/Consultant; AstraZeneca; EDE; Basilea: Grant/Research Support; Debiopharm, GSK; Affinium, Basilea,: Advisor/Consultant; Destiny, Amphliphi, Armata, Akagera: Advisor/Consultant; Merck; Contrafect; Karius; Janssen: Grant/Research Support; UpToDate: Royalties; Valanbio: Stock options
Dr. Fowler is Florence McAlister Distinguished Professor of Medicine and Professor of Molecular Genetics and Microbiology at Duke University. Dr. Fowler’s research in S. aureus and antibacterial resistance has led to >20 years (1999-2026) of continuous NIH funding as PI. He has been Contact PI of the Antibacterial Resistance Leadership Group (ARLG) since its inception in 2013. Under Dr Fowler’s leadership, the ARLG went from creation in 2013 to over 65 studies involving >28,000 patients from >130 sites in 12 countries producing >120 publications and 2 FDA approvals. He created the S. aureus Bacteremia Group, the world’s largest prospective biorepository of S. aureus bacteremia. He co-founded the International Collaboration on Endocarditis (ICE), and published the critical observation that S. aureus is now the leading cause of endocarditis in the industrialized world. He was lead (daptomycin, 2006) and senior (ceftobiprole, 2023) author on the only Phase 3 trials that successfully achieved an FDA indication for S. aureus bacteremia. He received the Clinical Research Achievement Award for publishing one of the top ten clinical research papers in the US in 2012, and the Translational Research Mentoring Award from Duke University School of Medicine in 2018. He has over 450 peer reviewed publications, over 40,000 citations, and a Web of Science h-index of 94.